FDA Guidance Aims To Advance, Facilitate Rare Disease R&D
This article was originally published in Scrip
Executive Summary
Even though orphan drugs have been declared the new blockbusters – with several companies cashing in big on the products – the FDA said most firms pursuing rare disease treatments still need some guidance in addressing certain particular common challenges.